18th September 2017
article written by
Cell Medica

Cell Medica announces the appointment of Luis Borges, PhD, as Chief Scientific Officer

Cell Medica Announces the appointment of Luis Borges, PhD, as Chief Scientific Officer (CSO) to accelerate R&D for CAR and TCR programmes Luis Borges, CSO will spearhead the Company’s global research group, including teams in London, Zurich and Houston. Luis brings extensive knowledge of cancer immunotherapy from twenty years of experience in the field, including […]

Read Full Article
20th June 2017
article written by
Cell Medica

Cell Medica acquires WT1 cancer immunotherapy from Cell and Gene Therapy Catapult

Cell Medica acquires WT1 cancer immunotherapy from Cell and Gene Therapy Catapult Acquisition transfers rights for WT1-TCR cell therapy from CGT Catapult to Cell Medica Collaboration for development, scale-up and manufacturing also established London, 20 June 2017 – Cell Medica today announced the acquisition of Catapult Therapy TCR Limited, a subsidiary of Cell and Gene […]

Read Full Article
16th March 2017
article written by
Cell Medica

£60 million Series C financing to advance multiple cancer programmes

£60 million Series C financing to advance multiple cancer programmes London, UK – 16 March 2017: Cell Medica (or ‘the Company’), a leading cellular immunotherapy company, has closed a £60 million Series C investment round with participation from existing investors Touchstone Innovations, funds managed by Invesco Perpetual, and funds managed by Woodford Investment Management. Cell […]

Read Full Article
21st February 2017
article written by
Cell Medica

Lead cancer immunotherapy candidate receives FDA fast track designation

Lead cancer immunotherapy candidate receives FDA fast track designation London, UK and Houston, TX, US – February 21, 2017. Cell Medica, a leader in developing cellular immunotherapy for the treatment of cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead oncology product CMD-003 for patients with […]

Read Full Article